ProCE Banner Activity

My Take on Recent Developments in Antibody‒Drug Conjugates for NSCLC

Clinical Thought

Read this commentary for an expert’s perspective on the clinical potential of approved and investigational antibody‒drug conjugates targeting HER2, HER3, TROP-2, and beyond.

Released: October 30, 2023

Share

Faculty

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Stephen V. Liu, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharma, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher: AbbVie, Alkermes, Elevation Oncology, Ellipses, Nuvalent, Genentech, Gilead, Merck, Merus, RAPT, Turning Point Therapeutics.